Celldex Therapeutics’ (CLDX) “Buy” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report sent to investors on Thursday morning,Benzinga reports. The firm currently has a $68.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $58.00.

A number of other research analysts also recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Barclays lifted their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $44.20.

Celldex Therapeutics Trading Down 1.8%

Shares of CLDX stock opened at $30.09 on Thursday. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.24. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $31.31. The stock’s fifty day simple moving average is $25.70 and its 200-day simple moving average is $25.52.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative return on equity of 39.67% and a negative net margin of 3,446.88%.The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $1.53 million. On average, sell-side analysts predict that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 39.3% during the fourth quarter. Wellington Management Group LLP now owns 8,079,608 shares of the biopharmaceutical company’s stock valued at $219,442,000 after buying an additional 2,279,605 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Celldex Therapeutics by 781.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $35,612,000 after acquiring an additional 1,551,354 shares during the last quarter. Braidwell LP increased its holdings in shares of Celldex Therapeutics by 214.0% during the 4th quarter. Braidwell LP now owns 1,858,109 shares of the biopharmaceutical company’s stock valued at $50,466,000 after acquiring an additional 1,266,420 shares during the last quarter. Elmind Capital LP bought a new position in shares of Celldex Therapeutics in the 4th quarter valued at approximately $23,493,000. Finally, State Street Corp lifted its holdings in Celldex Therapeutics by 19.5% in the 4th quarter. State Street Corp now owns 3,397,713 shares of the biopharmaceutical company’s stock worth $92,282,000 after purchasing an additional 555,579 shares during the last quarter.

Key Celldex Therapeutics News

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: New Phase 2 clinical data for barzolvolimab presented at AAAAI show sustained off‑treatment efficacy in chronic spontaneous urticaria (CSU) and meaningful quality‑of‑life gains in cold urticaria/symptomatic dermographism — potential upside for future regulatory/label discussions and commercial prospects. Celldex Presents Additional Positive Data
• Positive Sentiment: Analyst bullishness: Stifel reaffirmed a Buy and raised its price target to $68, and Morgan Stanley reiterated a Buy — these upgrades/support increase the stock’s upside narrative for investors focused on clinical catalysts. Stifel Reaffirms Buy, Raises PT
• Positive Sentiment: Sell‑side coverage remains constructive overall (average rating around “Moderate Buy”), which can sustain interest into upcoming 2026 data readouts and EMBARQ enrollment updates. TipRanks / Analyst Note
• Neutral Sentiment: HC Wainwright published EPS forecasts for FY2026/FY2027 (negative EPS expected), providing modeling detail but no change in clinical outlook; useful for valuation but not an immediate catalyst. HC Wainwright Estimates (MarketBeat)
• Neutral Sentiment: Mixed media and analyst commentary (Beaumont Enterprise, AmericanBankingNews) reinforce analyst interest but do not add new clinical or financial surprises. Q4 Snapshot
• Negative Sentiment: Recent Q4 2025 financials disappointed: the company missed EPS and revenue expectations, reported very large negative margins and negative ROE, and consensus still expects meaningful losses for 2026 — headwinds for near‑term sentiment and valuation. Q4 and Year‑End 2025 Results
• Negative Sentiment: Short interest data posted recently are inconsistent/odd (reported as zero), which may create temporary noise but reflects no clear short‑pressure signal.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.